Agenus Inc (AGEN) : Shikiar Asset Management Inc reduced its stake in Agenus Inc by 4.76% during the most recent quarter end. The investment management company now holds a total of 10,000 shares of Agenus Inc which is valued at $42,800 after selling 500 shares in Agenus Inc , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Agenus Inc makes up approximately 0.02% of Shikiar Asset Management Inc’s portfolio.
Agenus Inc opened for trading at $4.12 and hit $4.31 on the upside on Wednesday, eventually ending the session at $4.2, with a gain of 1.20% or 0.05 points. The heightened volatility saw the trading volume jump to 8,39,188 shares. Company has a market cap of $363 M.
Other Hedge Funds, Including , Creative Planning reduced its stake in AGEN by selling 10,000 shares or 13.81% in the most recent quarter. The Hedge Fund company now holds 62,409 shares of AGEN which is valued at $267,111.
Many Wall Street Analysts have commented on Agenus Inc. Maxim Group Upgraded Agenus Inc on Mar 11, 2016 to ” Buy”, Price Target of the shares are set at $7.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform including Retrocyte Display technology which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines and its saponin-based vaccine adjuvants QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages including a series of CPMs in investigational new drug (IND)-enabling studies Prophage Series vaccine a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM) which is a form of brain cancer and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner GlaxoSmithKline (GSK).